New hope for overcoming acquired drug resistance

Morgan, Peter P.
May 1993
CMAJ: Canadian Medical Association Journal;5/15/1993, Vol. 148 Issue 10, p1713
Academic Journal
No abstract available.


Related Articles

  • Molecular Targets of Ovarian Carcinomas with Acquired Resistance to Platinum/Taxane Chemotherapy. Kurzeder, Christian; Sauer, Georg; Deissler, Helmut // Current Cancer Drug Targets;May2006, Vol. 6 Issue 3, p207 

    Ovarian cancer of epithelial origin remains one of the most lethal malignancies despite response rates of more than 80% in first-line combination chemotherapy with platinum drugs and taxanes following surgery. Poor overall prognosis is mainly due to acquired resistance of the recurring tumor...

  • Trials for drug that gets to heart of HIV. Coghlan, Andy // New Scientist;6/10/2006, Vol. 190 Issue 2555, p16 

    The article offers information on a revolutionary drug that could help overcome HIV's growing resistance to existing antiviral drugs is about to be tested in combination with standard antivirals. Called PA-457, it is the first of a new class of anti-HIV compounds called maturation inhibitors. Up...

  • Aminoglycoside Antibiotic Resistance by Enzymatic Deactivation. Smith, Clyde A.; Baker, Edward N. // Current Drug Targets - Infectious Disorders;Jun2002, Vol. 2 Issue 2, p143 

    Acquired resistance to the aminoglycoside family of antibiotics has rendered this large and important family of compounds virtually unusable. Resistance is primarily mediated by three classes of enzymes, typically residing on transposable elements in resistant bacteria. These enzymes, the...

  • Glioblastoma Multiforme Therapy and Mechanisms of Resistance. Ramirez, Yulian P.; Weatherbee, Jessica L.; Wheelhouse, Richard T.; Ross, Alonzo H. // Pharmaceuticals;Dec2013, Vol. 6 Issue 12, p1475 

    Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent...

  • Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. Gower, Arjan; Wang, Yisong; Giaccone, Giuseppe // Journal of Molecular Medicine;Jul2014, Vol. 92 Issue 7, p697 

    In the past decade, a shift toward targeted therapies in non-small-cell lung cancer following molecular profiling has dramatically changed the way advanced adenocarcinoma is treated. However, tumor cells inevitably acquire resistance to such therapies, circumventing any sustained clinical...

  • Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. Gallagher, Stuart J.; Tiffen, Jessamy C.; Hersey, Peter // Cancers;Dec2015, Vol. 7 Issue 4, p1959 

    The treatment of melanoma has been revolutionized by new therapies targeting MAPK signaling or the immune system. Unfortunately these therapies are hindered by either primary resistance or the development of acquired resistance. Resistance mechanisms involving somatic mutations in genes...

  • Molecular Aspects of Resistance to Biological and Non-Biological Drugs and Strategies to Overcome Resistance in Colorectal Cancer. Troiani, T.; Martinelli, E.; Napolitano, S.; Morgillo, F.; Belli, G.; Cioffi, L.; Ciardiello, F. // Current Medicinal Chemistry;May2014, Issue 14, p1639 

    A number of successful systemic therapies are available for the treatment of disseminated cancers. However, tumor response is often transient, and therapy frequently fails due to emergence of resistant populations. The latter reflects the temporal and spatial heterogeneity of the tumor...

  • A role for intracellular immunization in chemosensitization of tumor cells? Piché, A; Rancourt, C // Gene Therapy;Jul99, Vol. 6 Issue 7, p1202 

    Acquired drug resistance represents a major cause of chemotherapy failure in patients with cancer. The characterization of the molecular pathways involved in drug resistance has provided us with new targets to overcome this problem. Many of these target proteins are often overexpressed in human...

  • Alkaloid-Metal Based Anticancer Agents. Chen, Zhen-Feng; Liu, Yan-Cheng; Huang, Ke-Bin; Liang, Hong // Current Topics in Medicinal Chemistry;Sep2013, Vol. 13 Issue 17, p2104 

    In order to overcome the significant side effects and the acquired resistance of platinum-based anticancer drugs, great efforts have been devoted to designing new platinum compounds or non-platinum transition metal anticancer complexes with improved pharmacological properties and a broader range...

  • Resistance to Imatinib in Chronic Myeloid Leukemia and Therapeutic Approaches to Circumvent the Problem. Breccia, Massimo; Alimena, Giuliana // Cardiovascular & Haematological Disorders - Drug Targets;Mar2009, Vol. 9 Issue 1, p21 

    The majority of patients with chronic phase chronic myeloid leukaemia (CP-CML) treated with imatinib achieves cytogenetic disease remission. Molecular monitoring for residual disease has prognostic significance: rising BCR-ABL levels may provide earliest indication that a patient has become...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics